Clinical trial · Interventional
Value of Screening MRI Brain in Stage IV Non-small Cell Lung Cancer
ValUe of Screening MRI Brain in Patients With Newly Diagnosed Stage IV Non-oncogene Addicted Non-small Cell Lung CANcer - The VULCAN Trial
NCT05864794CI-TRIAL-00114162VULCANrecruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Patients with newly diagnosed stage IV non-oncogene addicted NSCLC, who are fit for systemic treatment and don't have any symptoms of brain disease will undergo an MRI of the brain to screen for brain disease.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non Small Cell Lung Cancer Metastatic | Brain Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MRI | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Screening population
- description
- Patients with newly diagnosed stage IV non-oncogene addicted NSCLC, who are fit for systemic treatment and don't have any symptoms of brain disease.
- interventionNames
- Diagnostic Test: MRI
Primary outcomes (1)
- measure
- Clinical value of the MRI
- timeFrame
- up to 6 months after the MRI
- description
- Clinical value of the MRI evaluated by the treating thoracic oncologist and assessed by questionnaires completed on three timepoints.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically or cytologically confirmed stage IV metastatic NSCLC, not amenable to curative treatment. * Fit for systemic treatment (PS 0-2) according to standard of care. * No symptoms of brain disease disease assessed according to standard clinical care by the thoracic oncologist. Exclusion Criteria: * Prior/concomitant therapy for stage IV disease. * Oncogenic diver mutation (e.g. EGFR, ALK, ROS1, RET, MET, and BRAF) with approved targeted treatment. * Contraindications for MRI scan with contrast as per standard of care protocol of the institution.
References
Publications (0)
Data not yet available
No reference posted for this study.